COVID-19 in patients with airways disease: COPD, asthma and bronchiectasis

Abstract

COPD, asthma and bronchiectasis patients are an increased risk of respiratory infections, and in 2020 they were assumed to be more vulnerable to COVID-19 morbidity and mortality. However, evidence suggests that these patients were not over-represented among those hospitalised during the pandemic, although considerable variability in prevalence has been observed. COPD is associated with increased mortality and more severe outcomes from COVID-19, potentially related to increased expression of ACE2, the primary receptor for SARS-CoV-2 entry into host cells. Whether asthma increases the risk of severe COVID-19 is less clear, and evidence suggests that a type 2 high endotype may offer some protection against SARS-CoV-2 infection. Currently, guidance suggests that the continuation of usual maintenance therapies, including inhaled corticosteroids and biologics, is safe in SARS-CoV-2 infection. Public health measures taken during the COVID-19 pandemic reduced the circulation of other respiratory viruses and, as a consequence, reduced the frequency of exacerbations, including hospitalisations, for people with airways diseases.

Rights

This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.

Cite as

Downloadable citations

Identifiers

DOI

https://doi.org/10.1183/2312508X.10005024

Repository URI

https://discovery.dundee.ac.uk/en/publications/06896195-2075-498c-8003-e5f69af04620